Consolidated Financial Statements, Supplementary Information and Report of Independent Certified Public Accountants

TidalHealth, Inc.

June 30, 2024 and 2023



Contents		Page
	Report of Independent Certified Public Accountants	3
	Consolidated Financial Statements	
	Consolidated balance sheets	6
	Consolidated statements of operations and changes in net assets	8
	Consolidated statements of cash flows	10
	Notes to consolidated financial statements	11
	Supplementary Information	
	Consolidating balance sheet	39
	Consolidating statement of operations	41



GRANT THORNTON LLP

Two Commerce Square 2001 Market St., Suite 700 Philadelphia, PA 19103-7065

D +1 215 561 4200 **F** +1 215 561 1066

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

Board of Directors TidalHealth, Inc.

Opinion

We have audited the consolidated financial statements of TidalHealth, Inc. and subsidiaries, (the "Health System"), which comprise the consolidated balance sheets as of June 30, 2024 and 2023, and the related consolidated statements of operations and changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Health System as of June 30, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for opinion

We conducted our audits of the consolidated financial statements in accordance with auditing standards generally accepted in the United States of America ("US GAAS"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Health System and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of management for the financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Health System's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.



Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design
 audit procedures that are appropriate in the circumstances, but not for the
 purpose of expressing an opinion on the effectiveness of the Health System's
 internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Health System's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control–related matters that we identified during the audit.



Supplementary Information

The accompanying consolidating balance sheet as of June 30, 2024 and the related consolidating statement of operations for the year then ended are presented for purposes of additional analysis, rather than to present the financial position, results of operations, and cash flows of the individual entities, and are not a required part of the consolidated financial statements. Such supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures. These additional procedures included comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Philadelphia, Pennsylvania October 31, 2024

Sant Thornton LLP

CONSOLIDATED BALANCE SHEETS

June 30, (Dollar amounts in thousands)

	2	024	2023
ASSETS			
Current assets			
Cash and cash equivalents	\$	60,002	\$ 34,519
Short-term investments		6,617	5,848
Assets limited as to use		1,186	1,278
Patient accounts receivable		116,008	91,714
Supplies		19,277	16,731
Prepaids and other		16,868	 14,393
Total current assets		219,958	164,483
Investments		442,877	413,304
Assets limited as to use			
Under debt agreement		30,682	34,831
Self-insurance fund		58,274	52,429
Donor-restricted fund		66,670	 60,675
		155,626	147,935
Property and equipment, net		278,206	290,869
Other assets		39,122	 41,624
Total assets	<u>\$ 1</u>	,135,789	\$ 1,058,215

CONSOLIDATED BALANCE SHEETS - CONTINUED

June 30, (Dollar amounts in thousands)

	2024	2023
LIABILITIES AND NET ASSETS	 	
Current liabilities		
Current portion of long-term debt	\$ 5,971	\$ 6,042
Current portion of lease liability	1,056	885
Current portion of self-insurance liabilities	1,067	1,155
Accounts payable	38,193	36,330
Accrued liabilities	47,533	47,820
Advances from third-party payors	 21,192	10,230
Total current liabilities	115,012	102,462
Long-term debt, less current portion	215,187	221,908
Lease liability, less current portion	2,781	2,103
Self-insurance liabilities, less current portion	39,863	36,681
Accrued retirement benefits	4,409	3,445
Other liabilities	 2,943	1,924
Total liabilities	380,195	368,523
Net assets		
Without donor restrictions	683,317	623,976
With donor restrictions	 72,277	65,716
Total net assets	 755,594	 689,692
Total liabilities and net assets	\$ 1,135,789	\$ 1,058,215

CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS

Years ended June 30, (Dollar amounts in thousands)

	2024	2023
Net assets without donor restrictions		
Revenue		
Patient service revenue	\$ 827,398	\$ 772,740
Other revenue	 28,865	 22,830
Total revenue	856,263	795,570
Expenses		
Salaries and wages	411,821	399,697
Supplies and other expenses	340,308	324,383
Employee benefits	71,375	78,497
Depreciation and amortization	36,079	39,435
Interest	 6,664	 6,870
Total expenses	 866,247	 848,882
Loss from operations before other items	(9,984)	(53,312)
Other items		
Investment return	56,364	38,755
Other	 1,120	 3,307
Total other items	 57,484	 42,062
Excess of (deficiency in) revenue over expenses	47,500	(11,250)

Continued on next page

CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS - CONTINUED

Years ended June 30, (Dollar amounts in thousands)

	2024	 2023
Net assets without donor restrictions - continued		
Excess of (deficiency in) revenue over expenses (from previous page)	\$ 47,500	\$ (11,250)
Other changes in net assets without donor restrictions		
Net assets released from restrictions	2,889	4,358
Other	335	(61)
Other changes in accrued retirement benefits	 8,617	 3,541
Increase (decrease) in net assets without donor restrictions	59,341	(3,412)
Net assets with donor restrictions		
Contributions	2,848	2,135
Net realized gains on investments	3,041	2,336
Change in unrealized gains and losses on investments	3,730	3,328
Net assets released from restrictions	(3,058)	 (4,700)
Increase in net assets with donor restrictions	6,561	 3,099
INCREASE (DECREASE) IN NET ASSETS	65,902	(313)
Net assets at beginning of year	689,692	 690,005
Net assets at end of year	\$ 755,594	\$ 689,692

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years ended June 30, (Dollar amount in thousands)

Adjustments to reconcile Increase (decrease) in net assets to net cash used in operating activities: Depreciation and amortization 36,079 39,4 Other changes in accrued retirement benefits (8,617) (3,5 Amortization of original issue premium and financing costs (724) (7 Equity in earnings of unconsolidated joint ventures (3,431) (2,9 Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures (2,848) (2,1 Changes in operating assets and liabilities: Patient accounts receivable (24,294) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities (5,918) 13,0 Accounts payable and accrued liabilities (4,113) (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net	(313) 9,436 3,580)
Adjustments to reconcile Increase (decrease) in net assets to net cash used in operating activities: Depreciation and amortization 36,079 39,4 Other changes in accrued retirement benefits (8,617) (3,5 Amortization of original issue premium and financing costs (724) (7 Equity in earnings of unconsolidated joint ventures (3,431) (2,9 Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures (2,848) (2,1 Changes in operating assets and liabilities: Patient accounts receivable (24,294) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities (5,918) 13,0 Accounts payable and accrued liabilities (4,113) (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net	9,436
used in operating activities: Depreciation and amortization Other changes in accrued retirement benefits Amortization of original issue premium and financing costs (724) (7724) Equity in earnings of unconsolidated joint ventures (3,431) (2,5) Gain on sale of unconsolidated joint venture (3,291) (2,5) Losses on sale of property and equipment - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2) Distributions from unconsolidated joint ventures 2,696 (2,4) Proceeds from restricted contributions (2,848) (2,1) Changes in operating assets and liabilities: Patient accounts receivable Accounts payable and accrued liabilities Patient accounts receivable Accounts payable and accrued liabilities Accounts payable and accrued liabilities 4,113 (2,4) Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 Net cash provided by (used in) operating activities Pinvesting activities: Change in investments and assets limited as to use Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net	,
Depreciation and amortization 36,079 39,4 Other changes in accrued retirement benefits (8,617) (3,5 Amortization of original issue premium and financing costs (724) (7 Equity in earnings of unconsolidated joint ventures (3,431) (2,9 Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment - - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions (2,848) (2,1 Changes in operating assets and liabilities: (2,848) (2,1 Patient accounts receivable (24,294) (14,2 (14,2 Supplies and other assets (5,918) 13,0 (2,6 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 5,0 Accrued retirement benefits 9,581 7,2 (7 Advances from third-party payors 10,962 2 <td>,</td>	,
Other changes in accrued retirement benefits (8,617) (3,5) Amortization of original issue premium and financing costs (724) (7 Equity in earnings of unconsolidated joint ventures (3,431) (2,9 Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions (2,848) (2,1 Changes in operating assets and liabilities: (2,2494) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5 Investing activities: 7,436 <td>,</td>	,
Amortization of original issue premium and financing costs (724) (7 Equity in earnings of unconsolidated joint ventures (3,431) (2,9 Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment -	3 580)
Equity in earnings of unconsolidated joint ventures (3,431) (2,9 Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions (2,848) (2,1 Cannows and a contributions (2,848) (2,848) (2,1 Cannows and a contributions (2,4 Cannows and a contributions (2,4 Cannows and a contributions (2,4 Cannows and a contributions and a contributions (2,4 Cannows and a contributions (2,4 Cannows and a contributions and a contribution (2,4 Cannows and a contributions (2,4 Cannows and a contribution (2,4 Cannows and a contribu	,
Gain on sale of unconsolidated joint venture (3,291) (2,9 Losses on sale of property and equipment - - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions (2,848) (2,1 Congres) Changes in operating assets and liabilities: Patient accounts receivable (24,294) (14,2 Congres) (14,2 Congres) (5,918) 13,0 Congres) 1,576 5,0 Congres) 5,918 13,0 Congres) 1,576 5,0 Congres) 2,50 1,174 2,5 1,574 2,5	(736)
Losses on sale of property and equipment - 1 Net realized and unrealized gains and losses on investments (60,772) (43,2 Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions (2,848) (2,1 Changes in operating assets and liabilities: (24,294) (14,2 Patient accounts receivable (24,294) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5 Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5 Purchases of property and equipment, net (23,307) (30,4	2,968)
Net realized and unrealized gains and losses on investments Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions Changes in operating assets and liabilities: Patient accounts receivable Supplies and other assets Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts payable and right of use assets, net Other liabilities Lease liability and right of use assets, net Advances from third-party payors Net cash provided by (used in) operating activities Change in investments and assets limited as to use Return of (investment in) unconsolidated joint ventures Purchases of property and equipment, net (43,2 (43,2 (44,294) (14,2 (24,294) (14,2	2,968)
Distributions from unconsolidated joint ventures 2,696 2,4 Proceeds from restricted contributions (2,848) (2,1 Changes in operating assets and liabilities: Patient accounts receivable (24,294) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	153
Proceeds from restricted contributions (2,848) (2,1 Changes in operating assets and liabilities: (24,294) (14,2 Patient accounts receivable (24,294) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5 Investing activities: 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5 Purchases of property and equipment, net (23,307) (30,4)	3,244)
Changes in operating assets and liabilities: Patient accounts receivable (24,294) (14,2 Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	2,455
Patient accounts receivable (24,294) (14,294) Supplies and other assets (5,918) 13,00 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5 Investing activities: 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5 Purchases of property and equipment, net (23,307) (30,4)	2,135)
Supplies and other assets (5,918) 13,0 Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	
Accounts payable and accrued liabilities 1,576 5,0 Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	1,291)
Accrued retirement benefits 9,581 7,5 Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	3,032
Other liabilities 4,113 (2,4 Lease liability and right of use assets, net 729 (7 Advances from third-party payors 10,962 2 2 Net cash provided by (used in) operating activities 21,743 (2,5 Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5 Purchases of property and equipment, net (23,307) (30,4 Purchases of property and equipment, net (23,307) (30,4 Purchases of property and equipment, net (2,5 Purchases of property and equipment, net (2,5 Purchases of property and equipment, net (23,307) (30,4 Purchases of property and equipment, net (24,5 Purchases of property and equipment, net (24,5 Purchases of property and equipment, net (25,5 Purchases of property and equipment)	5,041
Lease liability and right of use assets, net Advances from third-party payors Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use Return of (investment in) unconsolidated joint ventures Purchases of property and equipment, net (23,307) (30,4)	7,591
Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	2,490)
Advances from third-party payors 10,962 2 Net cash provided by (used in) operating activities 21,743 (2,5) Investing activities: Change in investments and assets limited as to use 22,831 58,8 Return of (investment in) unconsolidated joint ventures 7,436 (2,5) Purchases of property and equipment, net (23,307) (30,4)	(759)
Investing activities: Change in investments and assets limited as to use Return of (investment in) unconsolidated joint ventures Purchases of property and equipment, net 22,831 58,8 (2,5) (30,4)	278
Change in investments and assets limited as to use22,83158,8Return of (investment in) unconsolidated joint ventures7,436(2,5Purchases of property and equipment, net(23,307)(30,4)	2,530)
Return of (investment in) unconsolidated joint ventures 7,436 (2,5 Purchases of property and equipment, net (23,307) (30,4	
Purchases of property and equipment, net (23,307) (30,4	3,815
Purchases of property and equipment, net (23,307) (30,4	2,500)
Not each provided by investing activities 6.060 25.9),462 <u>)</u>
Net cash provided by investing activities 0,900 25,0	5,853
Financing activities:	
Proceeds from restricted contributions 2,848 2,1	2,135
Advances from third-party payors - Medicare Advances - (31,8	1,879)
· ····	5,842)
Net cash used in financing activities(3,220)(35,5	5,586)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 25,483 (12,2	2,263)
Cash and cash equivalents at beginning of year 34,519 46,7	6,782
Cash and cash equivalents at end of year \$ 60,002 \$ 34,5	1,519

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 1 - ORGANIZATION AND MISSION

TidalHealth, Inc. ("TidalHealth") is a not-for-profit Maryland membership corporation, that serves as the parent company to a group of affiliated non-profit and for-profit entities (collectively the "Health System"). The Health System's mission is to improve the health of communities of the eastern shore of Maryland, southern Delaware, northern Virginia and portions of the Delaware-Maryland-Virginia Peninsula (the "Delmarva Peninsula"). The Health System's group of affiliated non-profit and for-profit entities are as follows:

TidalHealth Peninsula Regional, Inc. ("TPR") is a not-for-profit 283 licensed bed, nonstock corporation founded in 1897 to serve the health care needs of its region. Service areas include the Maryland counties of Wicomico, Dorchester, Somerset, and Worcester; southern Delaware; and the northern Eastern Shore of Virginia.

TidalHealth Nanticoke, Inc. ("TN"), a not-for-profit 99-licensed bed hospital in Seaford, Delaware, serving the health care needs of Sussex County.

TidalHealth Medical Partners, LLC ("TMP"), a not-for-profit physician practice organization which operates a physician network providing integrated physician services for the Health System, including the following supporting not-for-profit physician practice organizations: TidalHealth Primary Care, LLC, TidalHealth Specialty Care, LLC and TidalHealth Physician Network ("TPN").

McCready Foundation, Inc., is a not-for-profit that operates the Alice Byrd Tawes Nursing Home ("Nursing Home"), a 76-licensed bed skilled nursing home and Chesapeake Cove Assisted Living Center ("Rehab Center"), a rehabilitation center and assisted living facility.

Peninsula Health Ventures, Inc. ("Health Ventures") is a for-profit corporation organized for the purpose of owning, developing, operating, and investing in health care enterprises on the Delmarva Peninsula.

Peninsula Women's Center, LLC d/b/a TidalHealth Surgery Center, operates an ambulatory surgery center.

Peninsula Regional Clinically Integrated Network, LLC participates in the Medicare Shared Savings Program as an Accountable Care Organization ("ACO"), providing Medicare beneficiaries on the Delmarva Peninsula with access to coordinated care.

TidalHealth Foundation, Inc. ("Foundation") is a not-for-profit, nonstock corporation organized to raise contributions exclusively for the benefit of charitable, educational, medical, and scientific purposes of the Health System.

Delmarva Peninsula Insurance Company ("DPIC"), is a Cayman Island captive insurance company that provides professional and general liability insurance to related TidalHealth affiliates.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Health System and all affiliated non-profit and for-profit entities as described in Note 1, with the exception of joint ventures where there is less than 50% control or where the Health System does not have the ability to exercise significant influence (see Note 9). All significant intercompany transactions have been eliminated.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant management estimates and assumptions are used in recording patient accounts receivable and patient service revenue, advances from third-party payors, useful lives of property and equipment, actuarial estimates for the accrued retirement benefits, professional and general liabilities and workers' compensation costs, the reported fair value of certain assets and liabilities and the allocation of functional expenses. Actual amounts could differ from those estimates.

Fair Value of Financial Instruments

Financial instruments consist of cash equivalents, patient accounts receivable, investments and assets limited as to use, accounts payable, accrued liabilities, advances from third-party payors and long-term debt. The carrying amounts reported in the consolidated balance sheets for cash equivalents, patient accounts receivable, investments and assets limited as to use, accounts payable, accrued liabilities, advances from third-party payors, approximate fair value. Management's estimate of the fair value of other financial instruments is described elsewhere in the notes to the consolidated financial statements.

Cash and Cash Equivalents

Cash and cash equivalents include surplus operating funds invested in money market funds and highly liquid corporate, U.S. government, and agency obligations, all with maturities of less than three months when purchased. At June 30, 2024 and 2023, certain cash balances with financial institutions exceeded Federal depository insurance limits. Management believes that credit risk related to these deposits is minimal.

Investments and Assets Limited as to Use

Fair values of all investments, including short-term investments, investments, and assets limited as to use are recorded as described in Notes 7 and 8. Short-term investments represent investments with contractual maturities within one year and current investments in money market funds that have been designated for investment purposes.

Assets limited as to use includes externally held assets held by trustees under a debt agreement and consists of those assets designated for the payments of construction projects, principal and interest due on indebtedness and cost of issuance, externally held assets held by trustees' self-insurance programs and assets internally held to meet donor's intentions. Assets limited as to use required to meet current liabilities have been classified as current assets on the consolidated balance sheets.

Investment return includes interest and dividends, realized gains and losses (the value of securities sold) based on the specific-identification method, and changes in unrealized gains and losses. Investment return on investments of restricted assets are added to or deducted from the appropriate restricted net assets when restricted as to use by the donor.

Patient Accounts Receivable

A receivable is recognized when there is an unconditional right to payment, subject only to the passage of time. Patient accounts receivable, including billed accounts and unbilled accounts, which have the unconditional right to payment, and estimated amounts due from third-party payors for retroactive adjustments, are recorded as receivables since the right to consideration is unconditional and only the passage of time is required before payment of that consideration is due. The estimated uncollectible

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

amounts are generally considered implicit price concessions that are recorded as a direct reduction to patient accounts receivable.

Supplies

Supplies are carried at the lower of cost or market, using the first-in, first-out method.

Property and Equipment

Property and equipment acquisitions are recorded at cost. Depreciation is provided over the estimated useful life of each class of depreciable asset and is computed using the straight-line method. Construction in progress represents amounts expended or incurred toward property and equipment projects that have not been completed. No depreciation has been recorded for these items. Interest cost incurred, net of investment income earned on borrowed funds, during the period of construction is capitalized as a component of the cost of acquiring those assets.

Software development costs that are incurred in the preliminary project stage for internal use software are expensed as incurred. During the development stage, direct consulting costs and payroll and payroll-related costs for employees that are directly associated with each project are capitalized and depreciated over the estimated useful life of the software once the software is ready for its intended use. Capitalized software is depreciated using the straight-line method over its estimated useful life, which is generally seven years. Replacements and upgrades and enhancements to existing systems that result in added functionality are capitalized, while maintenance and repairs are charged to expense as incurred.

Gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted donations. Absent explicit donor stipulations about how long those assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

Leases

Arrangements are determined if they are a lease at inception of the contract. Right-of-use ("ROU") assets represent the right to use the underlying assets for the lease term and lease liabilities represent the obligation to make lease payments arising from the leases. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. An estimated incremental borrowing rate, which is derived from information available at the lease commencement date, is used in determining the present value of lease payments. The rate is determined based on information obtained from its bankers, its secured debt fair value and publicly available data for instruments with similar characteristics.

The operating leases are primarily for real estate, including off-campus outpatient facilities, medical office buildings, and administrative offices, as well as office equipment. The real estate lease agreements typically have initial terms of 5 to 10 years, and equipment lease agreements typically have initial terms of three to five years. Leases with an initial term of 12 months or less ("short-term leases") are not recorded in the consolidated balance sheets.

Real estate leases may include one or more options to renew, with renewals that typically can extend the lease term from 5 to 10 years. The exercise of lease renewal options is at the Health System's sole discretion. In general, these renewal options are not considered to be reasonably likely to be exercised, therefore, renewal options are generally not recognized as part of right of use assets and lease liabilities.

Certain lease agreements for real estate include payments based on actual common area maintenance expenses. These variable lease payments are recognized in supplies and other expenses but are not included in the ROU asset or liability balances. The lease agreements do not contain any material residual value guarantees, restrictions or covenants.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If long-lived assets are deemed to be impaired, the impairment to be recognized is the amount by which the carrying amount of the assets exceeds the fair value. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. As of June 30, 2024, management believes that no revisions to the remaining useful lives or writedown of long-lived assets are required.

Other Assets

Other assets are comprised of:

	June 30,			
		2024		2023
Investments in unconsolidated joint ventures (Note 9) Right to use assets (Note 12) Split-dollar insurance agreement (Note 13) Reinsurance receivable (Note 14) Contributions receivable, net Other	\$	17,237 3,800 4,880 8,760 1,647 2,798	\$	20,647 3,680 4,381 9,190 1,420 2,306
	\$	39,122	\$	41,624

Estimated Self-Insurance Liabilities

The provision for estimated professional liability claims, general liability claims, and workers' compensation claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

Net Assets with Donor Restrictions

Certain net assets are temporarily restricted and whose use has been limited by donors to a specific time period or purpose.

Certain net assets have been permanently restricted by donors to be maintained by the Health System in perpetuity.

Performance Indicator

The performance indicator is the deficiency in revenue over expenses, which excludes net assets released from restrictions for property acquisitions net of transfers to restricted net assets and other changes in accrued retirement benefits.

Donor-Restricted Gifts

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. Conditional promises to give and indications of intentions to give are reported at fair value at the date the gift is received. The gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or the purpose of the restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported on the consolidated

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

statements of operations and changes in net assets as net assets released from restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as contributions in net assets without donor restrictions in the accompanying consolidated financial statements.

Patient Service Revenue

The Health System has the following agreements for patient services: for those provided at the TPR hospital campus, all payors are required to pay the Maryland Health Services Cost Review Commission ("HSCRC") approved rates; and for all other locations, patient services are based on negotiated agreements with third-party payors, including health insurance companies and rates set by government regulations (for payors such as Medicare and Medicaid) that provide for reimbursement at amounts different from established charges. Reimbursement methodologies include prospectively determined rates per discharge, per diem rates, reimbursed costs, and discounted charges.

Patient service revenues are recorded at the amounts that reflect the consideration to which the Health System expects to be entitled to in exchange for providing patient care for both the hospital and any employed physicians. These amounts are due from patients, third-party payors (including managed care organizations and government programs, i.e., Medicare and Medicaid), and others and they include variable consideration for retroactive adjustments due to settlement of future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations. Generally, patients and third-party payors are billed several days after the services are performed or shortly after discharge. Patient service revenue is recognized in the period in which the performance obligations are satisfied under contracts by transferring services to patients.

Performance obligations are determined based on the nature of the services provided. Revenues are recognized for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. This method provides an appropriate depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. Generally, performance obligations are satisfied over time related to patients receiving inpatient acute care services. Performance obligations are measured from admission to the point when there are no further services required for the patient, which is generally the time of discharge. Revenues are recognized for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services, when: (1) services are provided; and (2) when it is believed the patient does not require additional services.

Estimates of contractual adjustments and discounts based on government regulations, contractual agreements, discount policies and historical experience are recorded as explicit price concessions, as applicable. The estimates of implicit price concessions based on historical collection experience within each class of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The consolidated financial statement effects of using this practical expedient are not materially different from an individual contract approach.

Advertising Costs

The Health System expenses advertising costs as incurred. For the years ended June 30, 2024 and 2023, advertising costs were \$1,764 and \$2,164, respectively, which are included in supplies and other expenses in the accompanying consolidated statements of operations and changes in net assets.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Income Taxes

TidalHealth has been recognized as a supporting organization exempt from federal income tax under Section 501(c)(3) as described in Section 509(a)(3) of the Internal Revenue Code (the "Code"). TPR and TN have been recognized organizations exempt from federal income tax under Section 501(c)(3) as described in Sections 509(a)(1) and Section 170(b)(1)(A)(iii) of the Code. The Foundation has been recognized as an organization exempt from federal income tax under Section 501(c)(3) as described in Sections 509(a)(1) and Section 170(b)(1)(A)(vi) of the Code. TPN and the McCready Foundation, Inc. have been recognized as organizations exempt from federal income tax under Section 501(c)(3) as described in Section 509(a)(2) of the Code. The Health System is subject to tax on income unrelated to its exempt purpose, unless that income is otherwise excluded by the Code. Each organization has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions.

Peninsula Women's Center, LLC, Peninsula Regional Clinically Integrated Network, LLC, and TMP are limited liability companies with TidalHealth as sole member and are disregarded for income tax purposes. Health Ventures is a for-profit corporation, wholly owned by the Health System. DPIC is a Cayman Island captive insurance company. Under Cayman Islands tax regulations, no tax is imposed on DPIC for premium and investment income.

The Health System follows guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and measurement. This guidance provides that the tax effects from an uncertain tax position can only be recognized in the financial statements if the position is "more-likely-than-not" to be sustained if the position were to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged.

The Health System has determined that there are no material uncertain tax positions that require recognition or disclosure in the consolidated financial statements at June 30, 2024 and 2023.

Reclassifications

Certain amounts in the prior-year consolidated financial statements have been reclassified to be consistent with the current-year presentation.

NOTE 3 - IMPACT OF THE COVID-19 PANDEMIC

The Health System received grant payments, which are considered nonexchange transactions. As a result of COVID-19, the federal government distributed from the Federal Emergency Management Agency ("FEMA"), for the years ended June 30, 2024 and 2023, payments received of \$1,726 and \$1,915, respectively, are included in other revenue in the consolidated statements of operations and changes in net assets. These payments are subject to audit and compliance with federal and state regulations. The Health System believes it has met the conditions to retain these funds, and no amounts are reserved for repayment at June 30, 2024 and 2023. Future grant payments are uncertain at this time.

The CARES Act also provided for an expansion of the Medicare Accelerated and Advance Payment Program for patient services. Under the program, the Health System received the advance payments in April 2022. The recoupment period began in April 2021 and amounts billed to Medicare for services provided were offset against the advanced payments received until the advance were fully recouped by the Medicare program which occurred during the year ended June 30, 2023.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 4 - LIQUIDITY AND AVAILABILITY OF RESOURCES

The financial assets available for general expenditure within one year of the consolidated balance sheet date consist of the following:

	June 30,			
		2024		2023
Cash Short-term investments Patient accounts receivable Investments	\$	60,002 6,617 116,008 442,877	\$	34,519 5,848 91,714 413,304
	\$	625,504	\$	545,385

NOTE 5 - CHARITY CARE

The Health System provides care to patients who meet certain criteria under its charity care policy, without charge or at amounts less than its approved rates. Because the Health System does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue.

The Health System maintains records to identify and monitor the level of charity care and community service it provides. These records include the amount of charges foregone based on established rates for services and supplies furnished under its charity care and community service policies and the number of patients receiving services under these policies. The Health System provided \$11,171 and \$14,069 for the years ended June 30, 2024 and 2023, respectively, of charity care at full cost including direct and indirect costs, based on the actual charity population using its cost to charge ratio. The HSCRC includes components within the rates to partially compensate eligible providers for uncompensated care.

Additionally, the Health System provides a wide range of community services to the general public. These include but are not limited to the following: free health screenings for breast cancer, prostate cancer, skin cancer, diabetes, high blood pressure, high blood cholesterol, hearing loss and glaucoma; free educational programs on a variety of health care topics; health fairs and demonstrations; and networking and coordination of services for the needy, elderly, and disabled. These community services are offered at the Health System and at schools, businesses, and other locations throughout the Health System's service

NOTE 6 - PATIENT SERVICE REVENUE

The Health System disaggregates revenues from contracts with customers by type of service and payor source as this depicts the nature, amount, timing and uncertainty of its revenues and cash flows as affected by economic factors. Tables providing details of these factors are presented below.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Patient service revenue recognized from major payer sources based on primary insurance designation, is as follows:

	Years Ende	ed June 30,
	2024	2023
Medicare	53%	55%
Medicaid	19	20
Managed care	3	2
CareFirst Blue Cross Blue Shield	13	11
Other, including self-pay	12	12
	100%	100%

The composition of patient care service revenues by type of service for is as follows:

	Years Ende	ed June 30,
	2024	2023
Inpatient	32%	34%
Outpatient	45	42
Physician services	23	24
	100%	100%

For services provided at the TPR hospital campus, all payors are required to pay the HSCRC approved rates. Management believes that this program will remain in effect at least through June 30, 2025. The major third-party payors, as recognized by the HSCRC, are allowed discounts of up to 7.7% on approved rates. These charges are subject to review and approval by the HSCRC. The total rate of reimbursement for services to patients under the Medicare and Medicaid programs is based on a waiver arrangement between the Centers for Medicare and Medicaid Service and the HSCRC. This waiver arrangement will be in place as long as Maryland hospitals achieve certain savings and improvements, as defined. TPR has an agreement with the HSCRC to participate in its Global Budgeted Revenue ("GBR") program. GBR methodology encourages hospitals to focus on population health strategies by establishing a fixed annual revenue cap for each GBR hospital. The agreement is evergreen in nature and covers both regulated inpatient and outpatient revenues.

Under GBR, hospital revenue is known at the beginning of each fiscal year, and for the year ending June 30, 2025, is expected to be approximately \$638,920. Annual revenue is calculated from a base year and is adjusted annually for inflation, infrastructure requirements, population changes, performance in quality-based programs, and changes in levels of uncompensated care. Revenue may also be adjusted annually for market levels and shifts of services to unregulated services. The HSCRC's rate-setting methodology for hospital service centers that provide both inpatient and outpatient services and only outpatient services, consists of establishing an acceptable unit rate for defined inpatient and outpatient service centers within a hospital. The actual average unit charge for each service center is compared to the approved rate monthly and annually. Overcharges and undercharges due to either patient volume or price variances, adjusted for penalties where applicable, are applied to decrease (in the case of overcharges) or increase (in the case of undercharges) in future approved rates on an annual basis. TPR undercharged for the years ended June 30, 2024 and 2023, within the allowable corridor as specified in the GBR Agreement.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

The timing of the HSCRC's rate adjustments for TPR could result in an increase or reduction in rates due to the variances and penalties described above in a year subsequent to the year in which such items occurred, and there is at least a possibility that the amounts may be material. For both the years ended June 30, 2024 and 2023, approximately 44% respectively of the Health System's patient service revenue was subject to the HSCRC's regulations.

Inpatient acute care and outpatient services not located on the TPR hospital campus, including TN and certain other services not regulated by the HSCRC provided to Medicare and Medicaid program beneficiaries, are paid at prospectively determined rates per discharge or outpatient service. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors. Additionally, there are certain defined Medicare program pass-through items, and certain other costs provisionally reimbursed by Medicare, are paid based on a cost reimbursement methodology or tentative rate. These are ultimately subjected to certain cost limitations or contingent on actual data for the year, with final settlement determined after submission of annual cost reports by TN and audits thereof, by the programs' fiscal intermediaries.

The TN Medicare cost reports have been audited and finalized through June 30, 2021. Differences between the estimated settlements and the amounts settled are recorded in the year of settlement. Estimated favorable results of appeal items are recorded when realization is reasonably assured. These estimates are included in advances from third-party payors in the consolidated balance sheets. Management uses the expected-value method when determining these amounts. In the opinion of management, adequate provision has been made for any adjustment, which may result from the final settlement of these cost reports, and any appeal issues.

Laws and regulations governing the HSCRC, Medicare and Medicaid programs, which represent a substantial portion of the patient service revenues, are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. The Health System believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While there are no currently known regulatory inquiries, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action.

The following table sets forth the detail of patient service revenue:

	Years Ended June 30,			
	_	2024	-	2023
Gross patient service revenue	\$	1,390,782	\$	1,259,460
Less: revenue deductions: Charity care Contractual and other allowances Implicit price concessions	_	(17,998) (517,662) (27,724)		(20,796) (445,544) (20,380)
	\$	827,398	\$	772,740

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 7 - INVESTMENTS AND ASSETS LIMITED AS TO USE

Fair value of short-term investments, investments and assets limited as to use is summarized as follows:

	June 30,			
		2024		2023
Cash and cash equivalents U.S. government securities Corporate bonds Equity securities Private placement funds	\$	8,582 160,783 82,598 259,225	\$	23,975 134,470 ,82,607 256,678
Hedge Private equity Fixed income		69,163 18,631 7,324		58,097 9,677 2,861
Less: amounts required for current liabilities	<u> </u>	606,306 (1,186) 605,120	\$	568,365 (1,278) 567,087
		Years End	ed Ju	ne 30.
		2024		2023
Investment return Interest and dividend income Realized gains, net Changes in unrealized gains and losses Other	\$	2,507 27,248 26,753 (144)	\$	1,493 7,421 30,159 (318)
	\$	56,364	\$	38,755

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 8 - FAIR VALUE MEASUREMENTS

U.S. GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below.

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Health System has the ability to access.
- Level 2 Inputs to the valuation methodology include:

Quoted prices for similar assets or liabilities in active markets;

Quoted prices for identical or similar assets or liabilities in inactive markets;

Inputs other than quoted prices that are observable for the asset or liability; and

Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Health System believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The fair value of private placement funds has been determined using the net asset value ("NAV") of the funds as provided by the respective fund managers. The NAV is used as a practical expedient to estimate fair value and is excluded from the fair value hierarchy. The underlying investments of these funds consist of securities with readily determinable market values. As of June 30, 2024 and 2023, there were no withdrawal restrictions or unfunded commitments on investments reported at NAV.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

The following tables present assets measured at fair value, aggregated by level in the fair value hierarchy within which those measurements fall:

	June 30, 2024							
		Total		Level 1		Level 2		Level 3
Assets Cash and cash equivalents U.S. government securities Corporate bonds Equity securities	\$	8,582 160,783 82,598 259,225	\$	8,582 33,700 - 255,976	\$	127,083 82,598 3,249	\$	- - - -
Private placement funds (at NAV): Hedge Private equity Fixed income		511,188 69,163 18,631 7,325	\$	298,258	\$	212,930	\$	
	\$	95,119 606,306						
				June 3	30, 20			
		Total		Level 1		Level 2		Level 3
Α 1								
Assets Cash and cash equivalents U.S. government securities Corporate bonds Equity securities	\$	23,975 134,470 82,607 256,678	\$	23,736 36,747 - 317,161	\$	150 97,723 82,607	\$	- - - -
Cash and cash equivalents U.S. government securities Corporate bonds Equity securities	\$	134,470 82,607	\$	23,736 36,747	\$	97,723	\$ \$	- - - - -
Cash and cash equivalents U.S. government securities Corporate bonds	\$	134,470 82,607 256,678		23,736 36,747 - 317,161		97,723 82,607 -		- - - - -

The fair values of securities are determined by third-party service providers utilizing various methods depending on the specific type of investment. Where quoted prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Where significant inputs, including benchmark yields, broker-dealer quotes, issuer spreads, bids, offers, global curve, and measures of volatility, are used by these third-party dealers or independent pricing services to determine fair values, the securities are classified within Level 2.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 9 - INVESTMENTS IN UNCONSOLIDATED JOINT VENTURES

The Health System and physicians located throughout Maryland and Delaware have joined together, along with other non-related for-profit investors, to expand surgical and certain other services within the local communities through jointly owned ventures, as follows:

	Membership Percentage		ι	Investi Inconsoli Ven	date ture	ed Joint s	Equity Earnings in Unconsolidated Joint Ventures				
	June	e 30,		June 30,				Years Ended June 30,			
	2024	2023	_	2024	2023			2024		2023	
Health Ventures:											
Peninsula Imaging, LLC	50%	50%	\$	6,245	\$	6,159	\$	1,086	\$	1,435	
AHP Delmarva, LLP	50%	50%		1,125		1,148		769		844	
Genesis Healthcare - Salisbury,											
LLC	-	50%		-		3,562		585		(46)	
Peninsula Home Care, LLC	50%	50%		159		145		192		(56)	
PHC at Nanticoke, LLC	50%	50%		96		113		139		124	
YDI, Inc.	50%	50%		2,806		2,778		28		6	
Deerpointe	26.3%	26.3%		6,806		6,742		632		661	
			\$	17,237	\$	20,647	\$	3,431	\$	2,968	

Regardless of the proportionate ownership of capital investment in these ventures, all decisions are made by the respective venture's operating board. In each case, the operating board is composed equally of members appointed by the Health Ventures and the other investors as a group. Accordingly, these are accounted for on the equity method of accounting.

Equity for earnings (losses) in unconsolidated joint ventures for Health Ventures are included in other revenue on the consolidated statements of operations and changes in net assets, due to the type of operations of the joint venture.

During 2024, the Health System sold its entire 50% interest in Genesis Healthcare - Salisbury, LLC, to the other partner for \$7,438 and as a result of the transaction, a gain on sale of membership interests of \$3,291 was recognized in other revenue in the consolidated statement operations for the year ended June 30, 2024.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 10 - PROPERTY AND EQUIPMENT

A summary of property and equipment follows:

	Estimated Useful Lives (in Years)		June 30,			
			2024		2023	
Land Land improvements Buildings and improvements Fixed equipment	- 20 15 - 40 20	\$	21,644 14,008 380,446 44,051	\$	21,644 13,842 364,600 42,286	
Movable equipment	5 - 7		356,235		339,121	
· ·	•		816,384		781,493	
Less: accumulated depreciation			(553,795)		(518,785)	
Construction in progress			262,589 15,617		262,708 28,161	
		\$	278,206	\$	290,869	

Depreciation expense related to property and equipment for the years ended June 30, 2024 and 2023 was \$35,970 and \$39,327, respectively.

As of June 30, 2024, the Health System was committed to building and equipment purchases totaling approximately \$19,604.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 11 - LONG-TERM DEBT

Long-term debt consists of the following:

	June 30,			
		2024		2023
Maryland Health and Higher Educational Facilities Authority ("MHHEFA") Revenue Bonds: Series 2020A 4.00% to 5.00% serial and term bonds due in annual amounts ranging from \$1,405 to \$13,130 on July 1 of each year through 2048 Series 2015 5.00% serial bond due in the amount of \$2,800 on July 1, 2023	\$	91,395	\$	92,800
Bank Taxable Notes:				_,
Series 2021A 2.40% taxable note due in annual amounts ranging from \$1,035 to \$6,895 on July 1 of each year through 2045 Series 2021B 2.46% taxable note due in annual amounts ranging from \$250 to \$435 on July 1 of each year through 2045 Bank loan due monthly through May 2025 with a 4.60% fixed rate of interest Delaware Economic Development Authority Strategic Fund Loan,		119,195 7,645 296		120,240 7,890 693
maturing in varying annual amounts through December 2023, no stated interest rate		_		175
no stated interest rate		218,531		224,598
Less: current portion of long-term debt		(5,971)		(6,042)
Plus: unamortized original issue premiums Less: unamortized debt financing costs		212,560 4,400 (1,773)		218,556 5,233 (1,881)
Long-term debt, less current portion	\$	215,187	\$	221,908

Fair Value

The Health System uses quoted market prices in estimating the fair value of its long-term debt. The fair value of the long-term debt outstanding as of June 30, 2024 and 2023, was approximately \$223,678 and \$224,993, respectively.

Debt

The Revenue Bonds and the Bank Taxable Notes proceeds were used to advance refund or payoff previously outstanding debt obligations, finance capital purchases and pay the related financing cost. The premiums and financing cost from the issuance of the related debt are being amortized over the life of the debt.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Covenants

The Obligated Group, as amended for the 2020A and 2015 Bonds (collectively the "Bonds"), consists of TidalHealth, TPR and TN and the Obligated Group for the Series 2021A and B Taxable Notes (collectively the "Taxable Notes"), of TidalHealth, TPR, TN, and McCready Foundation, Inc. These Obligated Groups are required to make semiannual payments to the trustee and the bank sufficient to meet the annual debt service requirements.

As security for the debt service requirements of the Bonds and Taxable Notes, MHHEFA and the bank have a first lien and claim on all receipts of the Obligated Groups. The terms of the indenture agreements restrict the Obligated Groups' ability to create additional indebtedness and its use of the facilities and require the Obligated Groups to maintain stipulated insurance coverage and a rate structure in each year sufficient to meet certain rate covenant requirements. The Obligated Groups have complied with these financial covenants for the years ended June 30, 2024 and 2023.

Scheduled principal repayments on long-term debt for the years ending June 30, are as follows:

2025	\$ 5,971
2026	6,750
2027	6,985
2028	7,100
2029	7,305
2030 and thereafter	 184,420
	\$ 218,531

NOTE 12 - LEASES

The following table presents the components of the right of use assets and liabilities related to leases and their classification in the consolidated balance sheets:

	Classification in Consolidated		June 30,			
Component of Lease Balances Balance Sheets			2024		2023	
Assets						
Operating lease	Other assets	<u>\$</u>	3,800	\$	3,680	
Liabilities Operating lease						
Current Long-term	Current portion of lease liability Lease liability, net of current portion	\$	1,056 2,781	\$	885 2,103	
Ü	7.	\$	3,837	\$	2,988	

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

The following table presents the components of lease expense and their classification in the consolidated statements of operations and changes in net assets:

			·		00		
Component of Lease Balances	Classification in Consolidated Statements of Operations and Changes in Net Assets		Years Endo 2024	2023			
Component of Lease Balances	of Operations and Changes in Net Assets		2024		2023		
Operating lease expense	Supplies and other	\$	5,007	\$	6,054		
Variable and short-term lease expense	Supplies and other		969		947		
		\$	5,976	\$	7,001		
The weighted-average lease ter	ms and discount rates for operating leas	ses are a	as follows:				
	_		June 3	30,			
		202	4	2	023		
Weighted-average remaining looperating leases	3.51 ye	ears	2023 4.52 years 2.29%				
Weighted-average discount rate Operating leases	te	2.50%	%	2.2	9%		
Cash flow related to leases is as	s follows:						
	_	Yea	ars Ended	June	30,		
		20	24		2023		
Cash paid for amounts include liabilities: Operating cash outflows r	d in the measurement of lease elated to operating leases	8	6,031	\$	5,612		
The future minimum rental comm	mitments for all noncancelable operating	g leases	are as foll	lows:			
Years Ending June 30,							
2025 2026 2027 2028			-	\$	1,024 1,006 1,006 908		
					3,944		
Less: imputed interest			_		(107)		
					3,837		
Less: current portion			-		(1,056)		
			<u> </u>	\$	2,781		

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 13 - RETIREMENT BENEFIT PLANS

The Health System has a cash balance-type defined benefit pension plan, The Peninsula Regional Medical Center Pension Plus Plan (the "Plan"), covering substantially all of its employees. Plan benefits are based on years of service and the employees' compensation during the last five years of covered employment. The Health System's funding policy is to make sufficient contributions to the Plan to comply with the minimum funding provisions of the Employee Retirement Income Security Act of 1974. Contributions are intended to provide not only for benefits attributed to service to date but also for those expected to be earned in the future. The mortality table used for projecting the benefits obligation is the Pri-2012 white collar employee/retiree mortality with MP 2021 scale applied generationally for years ended June 30, 2024 and 2023.

The Plan provides annual allocations to a participant's hypothetical account. When a participant retires, the participant has the choice to receive a lump-sum distribution equal to the value of the hypothetical account or to receive an annuity based on the value of the hypothetical account.

The Plan provides three different allocations: (i) a service-related allocation; (ii) an age-related allocation; and (iii) a matching allocation for certain employees. Both the service-related allocation and the age-related allocation are determined by multiplying a participant's annual compensation by a certain percentage. The matching allocation operates to provide an annual allocation in the Plan based on the participant's contribution to the Health System's 403(b) plan.

TN had a qualified noncontributory defined benefit cash balance plan (the "TN Plan") that was frozen in January, 2009 and amended and terminated at June 30, 2022. On June 27, 2023 the TH Plan received a determination letter from the Internal Revenue Service authorizing the dissolution of the TN Plan with a 120-day window. All assets of the plan were disbursed during October 2023. As defined, all participants received a lump sum pay-out or an annuity purchased on their behalf, established on or before this disbursement date.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

The following provides a reconciliation of the changes in the projected benefit obligations and the fair value of plans assets, and plans funded status:

	June 30,							
	2024			2024		2023		2023
		The Plan		TN Plan		Γhe Plan		ΓN Plan
Accumulated benefit obligation	\$	151,784	\$		\$	152,756	\$	15,470
Projected benefit obligation, beginning of year Service cost Interest cost Actuarial gain Settlements Benefits paid	\$	157,686 11,303 7,980 (1,021) (9,975) (1,018)	\$	15,470 - 235 (534) (14,835) (336)	\$	152,755 10,787 6,761 (1,817) (9,931) (869)	\$	17,626 - 545 (181) (1,664) (856)
Projected benefit obligation, end of year		164,955		-		157,686		15,470
Fair value of plan assets, beginning of year Actual return on plan assets Employer contributions Settlements Benefits paid		155,156 16,384 - (9,975) (1,019)		15,066 14 91 (14,835) (336)		154,419 11,537 - (9,931) (869)		17,116 470 - (1,664) (856)
Fair value of plan assets, end of year		160,546				155,156		15,066
Funded status	\$	(4,409)	\$		\$	(2,530)	\$	(404)
Accrued retirement benefits	\$	(4,409)	\$		\$	2,530	\$	404
Net amounts recognized in net assets without donor restrictions:								
Net actuarial (gain) loss	\$	(14,521)	\$	-	\$	(6,938)	\$	1,034

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Components of net periodic benefit cost and changes in net asset without donor restrictions are as follows:

	Year Ended June 30,							
		2024		2024		2023		2023
	Т	he Plan		TN Plan		The Plan		TN Plan
Components of net periodic benefit cost recognized in employee benefits: Service cost Components of net periodic benefit gain recognized in other items:	\$	11,303	\$	-	\$	10,787	\$	-
Interest cost Expected return on plan		7,980		235		6,761		545
assets Settlement		(9,820)		(195) 682		(9,774)		(839) 149
		9,463		722		(3,013)		(145)
Net periodic benefit cost (gain)		9,463		722		7,774		(145)
Recognized in net assets without donor restrictions as other changes in other changes in accrued retirement benefits: Net actuarial (gain) loss		(7,583)		(1,034)		(3,580)		39
Total recognized in net periodic benefit cost (gain) and change in net assets without donor restrictions	\$	1,880	\$	(312)	\$	4,194_	\$	(106)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Weighted-average assumptions used to determine projected benefit obligations and net periodic benefit costs were as follows:

	June 30,								
	2024	2024	2023	2023					
	The Plan	TN Plan	The Plan	TN Plan					
Projected benefit obligation:									
Discount rate	5.45%	N/A	5.20%	4.80%					
Rates of increase in compensation									
levels:									
Service:									
<5	12.00%	N/A	12.00%	N/A					
5<20	4.50%	N/A	4.50%	N/A					
20=<	2.50%	N/A	2.50%	N/A					
Measurement Date	June 30	June 30	June 30	June 30					
	June 30,								
	2024	2024	2023	2023					
	The Plan	TN Plan	The Plan	TN Plan					
Net periodic benefit cost:									
Discount rate	5.20%	4.80%	4.55%	4.25%					
Expected long-term return on plan									
assets	6.25%	4.00%	6.25%	6.75%					
Rate of increase in compensation									
levels:									
Service:									
<5	12.00%	N/A	12.00%	N/A					
5<20	4.50%	N/A	4.50%	N/A					
20=<	2.50%	N/A	2.50%	N/A					

The defined benefit pension plan asset allocation as of the measurement date and the target asset allocation, presented as a percentage of total plan assets, were as follows:

		June 30,						
	2024	2023	2023	Target				
	The Plan	The Plan	TN Plan	Allocations				
Debt securities	28%	40%	54%	25% - 50%				
Equity securities	46%	42%	-	30% - 65%				
Alternative investments	23%	16%	-	20% - 30%				
Cash and cash equivalents	3%	2%	46%	-% - 5%				
Total	100%	100%	100%					

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

The Health System's defined benefit plan invests in a diversified mix of traditional asset classes. Investments in U.S. equity securities and fixed income securities are made to maximize long-term results while recognizing the need for adequate liquidity to meet ongoing benefit and administrative obligations. Risk tolerance of unexpected investment and actuarial outcomes is continually evaluated by understanding the pension plan's liability characteristics. This is performed through forecasting and assessing ranges of investment outcomes over short-term and long-term horizons, and by assessing the Health System's financial condition and its future potential obligations from both the pension and general operational requirements. Complementary investment styles, such as growth and value equity investing techniques, are utilized by the Health System's investment advisors to further improve portfolio and operational risk characteristics. Equity investments, both actively and passively managed, are used primarily to increase overall plan returns. Fixed income investments provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.

Asset allocations and investment performance are formally reviewed at regularly scheduled meetings of the Health System's Financial Resources Committee.

The overall rate of expected return on assets assumption was based on historical returns, with adjustments made to reflect expectations of future returns. The extent to which the future expectations were recognized included the target rates of return for the future, which have not historically changed.

The fair values of assets as of June 30, by asset category (see Note 8 for a description of the asset categories), are as follows:

	June 30, 2024							
		Total		Level 1		Level 2		Level 3
Assets - The Plan Investments at fair value: Cash and cash								
equivalents Fixed income	\$	4,424 45,724	\$	4,424 -	\$	- 45,724	\$	-
Equities and equity funds		74,174		74,174		<u> </u>		
Total Private placement funds (at NAV):		124,322	\$	78,598	\$	45,724	\$	<u>-</u>
Hedge funds		36,224						
Total	\$	160,546						

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

	June 30, 2023													
		Total		Level 1		Level 2		Level 3						
Assets - The Plan Investments at fair value: Cash and cash														
equivalents Fixed income	\$	9,848 46,113	\$	9,848 46,113	\$	-	\$	-						
Equities and equity funds		75,038		75,038		<u>-</u>		<u> </u>						
Total Private placement funds		130,999	\$	130,999	\$	29,129	\$	<u>-</u>						
(at NAV): Hedge funds		24,157												
Total	\$	155,156												
				June 3	0, 202	23								
		Total		Level 1	·	Level 2		Level 3						
Assets - TN Plan Investments at fair value: Cash and cash														
equivalents Bond mutual funds	\$	6,980 8,086	\$	6,980 8,086	\$	-	\$	-						
Total	\$	15,066	\$	15,066	\$	-	\$							

The following methods and assumptions were used to estimate the fair value of each class of financial instrument:

Fixed income: The fair value is estimated using quoted prices for similar assets in active markets or quoted prices for identical or similar assets in non-active markets (few transactions, limited information, noncurrent prices, and high variability over time).

Equities/equity funds: The fair value is determined by market quotes for an identical security in an observable market.

Hedge Funds: The fair value of private placement funds has been determined using the net asset value ("NAV") of the funds as provided by the respective fund managers. The NAV is used as a practical expedient to estimate fair value and is excluded from the fair value hierarchy. The underlying investments of these funds consist of securities with readily determinable market value and other hedge funds and private placement funds.

The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Health System believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

Cash Flows

The Health System does not expect to make voluntary contributions to the Plan, for the year ending June 30, 2025. This funding level exceeds any regulatory requirements. The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid as follows for the years ending June 30:

2025	\$ 9,792
2026	10,312
2027	11,043
2028	11,578
2029	12,774
2030 - 2034	70.023

Defined Contribution Plans

The Health System has a 403(b) defined contribution savings plan that includes all full-time and part-time employees. The Health System matches participant contributions for active participants as of December 31 who have completed at least 975 hours of service during the calendar year. The match is 25% of the first 1% of compensation for participants with 1 - 15 years of service and 50% of the first 2% for participants with more than 15 years of service. The Health System's contribution expense for the years ended June 30, 2024 and 2023 was \$2,555 and \$2,398, respectively.

The Health System has a jointly owned split dollar agreement with a key executive through an insurance company. Total funding as of June 30, 2024 and 2023, was \$4,880 and \$4,381, respectively which is recorded in other assets on the consolidated balance sheets. The value held by the insurance company along with additional security on the policy is collateral held to secure the return on the Health System's funding plus interest. The agreements allow for the key executives to borrow specified amounts to be repaid by the proceeds of the life insurance policies. Any remaining death proceeds are distributed to the executive's beneficiary as agreed upon by the parties.

NOTE 14 - COMMITMENTS AND CONTINGENCIES

Self-Insurance Liabilities and Litigation

DPIC provides Primary Medical Professional Liability ("MPL") and Primary General Liability ("GL") coverage to the Health System and its employed physicians on a mature claims-made basis. The primary MPL policy provides limits of liability of \$2,000 per occurrence with an \$8,000 annual aggregate. The primary GL policy provides limits of liability of \$1,000 per occurrence with a \$3,000 annual aggregate. The employed physicians are covered with retro dates consistent with their date of hire. This policy is retrospectively rated.

DPIC provides excess umbrella liability coverage on a mature claims-made basis with a retroactive date of March 1, 2005. The excess MPL coverage follows the form of the underlying MPL coverage providing a total of \$35,000 limits of liability. The umbrella liability coverage provides \$35,000 limits of liability in excess of scheduled underlying coverages. The excess umbrella liability coverage is 100% reinsured with an unrelated commercial insurance company for the first \$10,000 limit and another unrelated commercial insurance company for the second \$15,000 limit.

DPIC assumed the MPL and GL coverage previously included under the Health System's self-insurance plan (the "LPT"), for incidents occurring between March 1, 1986 and June 30, 2013 for MPL and for occurrences between March 1, 2004 and June 30, 2013 for GL, that were reported to TPR prior to June 30,

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

2013. The policy provides MPL coverage limits varying from \$1,000 to \$2,000 per occurrence, with policy aggregates varying from \$3,000 to \$8,000. The policy provides GL coverage limits of \$1,000 per occurrence and \$3,000 annual aggregates.

DPIC also provides employee benefit plan stop loss coverage to the Health System on a claims-made basis. DPIC covers liability in excess of \$350 per covered person with a \$100 deductible. DPIC's liability above \$250 is fully reinsured with an unrelated commercial reinsurance company.

The reserve for reported professional liability claims and claims incurred but not reported ("IBNR") are reported gross of expected insurance recoveries. The reserves for reported claims and claims IBNR are reported within the self-insured liabilities in the consolidated balance sheets. In addition, the expected insurance recoveries are reported as reinsurance receivable in other assets in the consolidated balance sheets.

Accrued claims activity related to MPL, GL and employee benefit plan, is as follows:

	Years End	ed June 30,			
	 2024		2023		
Accrued claims and IBNR - beginning of the year Less: reinsurance receivable	\$ 33,290 (9,190)	\$	33,911 (12,804)		
Accrued claims and IBNR, net - beginning of the year	24,100		21,107		
Incurred related to: Current year Prior year	7,100 (2,235)		6,350 3,591		
Total incurred	4,865		9,941		
Paid related to: Current year Prior year	 (43) (1,566)		(7) (6,941)		
Total paid	 (1,609)		(6,948)		
Accrued claims and IBNR, net - end of the year	27,356		24,100		
Add: reinsurance receivable	 8,760		9,190		
Accrued claims and IBNR - end of the year	\$ 36,116	\$	33,290		

The Health System is also self-insured for workers' compensation up to an annual limit of \$500 per occurrence. The Health System carries an excess liability insurance policy for workers' compensation claims above this limit. As of June 30, 2024 and 2023, \$4,531 and \$4,546, respectively, have been reserved for workers' compensation loss contingencies.

The Health System has been named as a defendant in various lawsuits arising from the performance of its normal activities. In the opinion of the Health System's management, after discussion with legal counsel, the amount, if any, of the Health System's ultimate liability under these lawsuits will not have a material adverse effect on the consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

A portion of the Health System's revenues is received from health maintenance organizations and other managed care payors. Managed care payors generally use case management activities to control utilization. These payors also have the ability to select providers offering the most cost-effective care. Management does not believe that the Health System has undue exposure to any one managed care payor.

NOTE 15 - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions are available for the following purposes:

	June 30,								
		2024		2023					
Subject to expenditure for specific purpose or time: Capital purposes Patient services	\$	38,120 16,036 9,543	\$	30,420 18,769 7,967					
Educational purposes Investments to be held in perpetuity, the income from which is expendable to support health care services	_	63,699 8,578		57,156 8,560					
	\$	72,277	\$	65,716					

NOTE 16 - CONCENTRATIONS OF CREDIT RISK

The Health System grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The mix of accounts receivable from patients and third-party payors is as follows:

	Years Ended June 30,							
	2024	2023						
Medicare	53%	54%						
Medicaid	19	21						
Managed care	13	12						
CareFirst Blue Cross Blue Shield	13	11						
Other, including self-pay	2	2						
	100%	100%						

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED

June 30, 2024 and 2023 (Dollar amounts in thousands)

NOTE 17 - FUNCTIONAL EXPENSES

The Health System considers health care services and general and administrative to be its primary functional categories for purposes of expense classification. The operating expenses by functional classification:

	Year Ended June 30, 2024										
		ealth Care Services		neral and ninistrative		Total					
Salaries and wages Supplies and other expenses Employee benefits Depreciation and amortization Interest	\$	367,084 301,711 63,487 32,201 5,950	\$	44,737 38,597 7,888 3,878 714	\$	411,821 340,308 71,375 36,079 6,664					
	\$	770,433	\$	95,814	\$	866,247					
		Year Ended June 30, 2023									
		ealth Care Services		neral and ninistrative	Total						
		Jei vices	Aun	III II SII ALI VE		Total					
Salaries and wages Supplies and other expenses Employee benefits Depreciation and amortization Interest	\$	356,186 290,005 69,873 35,195 6,132	\$	43,511 34,378 8,624 4,240 738	\$	399,697 324,383 78,497 39,435 6,870					
	\$	757,391	\$	91,491	\$	848,882					

NOTE 18 - SUBSEQUENT EVENTS

The Health System has evaluated its June 30, 2024 consolidated financial statements for subsequent events through October 31, 2024 the date the consolidated financial statements were issued. Management is not aware of any subsequent events which would require recognition or disclosure in the consolidated financial statements.



CONSOLIDATING BALANCE SHEET

June 30, 2024 (Dollar amounts in thousands)

	TidalHealth	TidalHealth Peninsula Regional	TidalHealth Nanticoke	Combined TidalHealth Medical Partners	McCready Foundation	Peninsula Health Ventures	TidalHealth Surgery Center	Peninsula Regional Clinically Integrated Network	TidalHealth Foundation	Delmarva Peninsula Insurance Company	Eliminations	Consolidated
ASSETS												
Current assets Cash and cash equivalents Short-term investments Assets limited as to use Intercompany receivables Patient accounts receivable Supplies Prepaids and other	\$ 5,065 959 60,843 - 405	\$ 26,912 6,617 1,529 67,396 13,488 12,201	\$ 1,172 - - 806 19,864 5,472 482	\$ 2,079 - 1,927 27,288 - 2,649	\$ 654 - - 56 701 40 40	\$ 16,372 - - - 166 - 72	\$ 275 - - - 593 277	\$ 6 - - - - -	\$ 2,067 - - - - -	\$ 5,400 - 227 - - - 1,019	\$ - - (65,161)	\$ 60,002 6,617 1,186 - 116,008 19,277 16,868
Total current assets	67,272	128,143	27,796	33,943	1,491	16,610	1,145	6	2,067	6,646	(65,161)	219,958
Investments	509	393,808	48,560	-	-	-	-	-	-	-	-	442,877
Investments in subsidiaries	764,027	-	-	-	-	-	-	-	-	-	(764,027)	-
Assets limited as to use Under debt agreement Self-insurance fund Donor-restricted fund	30,682 7,493	- - 60,159	- - -			- - -	- - -		- - 6,511	50,781 	- - -	30,682 58,274 66,670
	38,175	60,159	-	-	-	-	-	-	6,511	50,781	-	155,626
Property and equipment, net	-	162,590	86,877	14,314	9,840	3,934	651	-	-	-	-	278,206
Other assets	7,258	2,167	279	1,417		17,236			2,005	8,760		39,122
Total assets	\$ 877,241	\$ 746,867	\$ 163,512	\$ 49,674	\$ 11,331	\$ 37,780	\$ 1,796	\$ 6	\$ 10,583	\$ 66,187	\$ (829,188)	\$ 1,135,789

CONSOLIDATING BALANCE SHEET - CONTINUED

June 30, 2024 (Dollar amounts in thousands)

LIABILITIES AND NET ASSETS	Tidall	Health _	Peni	Health insula jional	TidalHealth Nanticoke		Combined TidalHealth Medical Partners		McCready Foundation		Peninsula Health Ventures		TidalHealth Surgery Center		Peninsula Regional Clinically Integrated Network		TidalHealth Foundation		Delmarva Peninsula Insurance Company		Eliminations		Consolidated	
Current liabilities																								
Current portion of long-term debt	\$	1,650	\$	3,745	\$	-	\$	-	\$	280	\$	296	\$	-	\$	-	\$	-	\$	-	\$	-	\$	5,971
Current portion of lease liability		-		613		65		378		-		-		-		-		-		-		-		1,056
Current portion self-insurance liabilities		1,013		54		-		-		-		-		-		-		-		-		-		1,067
Intercompany payables		-		43,729		5,116		-		-		1,929		-		-		387		4,000	(65	5,161)		-
Accounts payable		20,502		7,284		3,318		2,535		353		2,738		402		33		-		1,028		-		38,193
Accrued liabilities		9,989		21,333		2,961		12,663		344		30		150		63		-		-		-		47,533
Advances from third-party payors				20,836		300		<u> </u>		56						-		-		-				21,192
Total current liabilities		33,154		97,594	2	1,760		15,576		1,033		4,993		552		96		387		5,028	(65	5,161)		115,012
Long-term debt, less current portion		92,765		115,082		_		_		7,340		_		_		_		_		_		_		215,187
Lease liability, less current portion		-		1,553		179		1,049				_		_		_		_		_		_		2,781
Self-insured liabilities		3,748		-		-		-		-		-		-		-		-		36,115		-		39,863
Accrued retirement benefits		4,409		-		-		-		-		-		-		-		-				-		4,409
Other liabilities		1,782		30		438						663						30						2,943
Total liabilities	•	135,858		214,259	2	2,377		16,625		8,373		5,656		552		96		417		41,143	(65	5,161)		380,195
Net assets																								
Without donor restrictions	6	669,106		468.829	14	1,135		33,049		2,958		32,124		1,244		(90)		1,649		25,044	(69	1,731)		683,317
With donor restrictions		72,277		63,779												-		8,517		-		2,296)		72,277
Total net assets	7	741,383		532,608	14	1,135		33,049		2,958		32,124		1,244		(90)		10,166		25,044	(764	1,027)		755,594
Total liabilities and net assets	\$ 8	877,241	\$	746,867	\$ 16	3,512	\$	49,674	\$	11,331	\$	37,780	\$	1,796	\$	6	\$	10,583	\$	66,187	\$ (829	9,188)	\$ 1,	135,789

CONSOLIDATING STATEMENT OF OPERATIONS

Year ended June 30, 2024 (Dollar amounts in thousands)

	Tidal	Health	TidalHealth Peninsula Regional	TidalHealth Nanticoke	Combined TidalHealth Medical Partners	McCready Foundation	Peninsula Health Ventures	TidalHealth Surgery Center	Peninsula Regional Clinically Integrated Network	TidalHealth Foundation	Delmarva Peninsula Insurance Company	Eliminations	Consolidated
Net assets without donor restrictions Revenue													
Patient service revenue Other revenue Net assets released from restrictions	\$	3	\$ 522,211 8,728	\$ 160,452 4,921	\$ 131,432 4,995	\$ 7,697 814	\$ 1,470 7,060	\$ 4,136 - -	\$ - 2,344 -	\$ - - 3,059	\$ - 4,156 -	\$ - (4,156) -	\$ 827,398 28,865 3,059
Total revenue		3	530,939	165,373	136,427	8,511	8,530	4,136	2,344	3,059	4,156	(4,156)	859,322
Expenses Salaries and wages Supplies and other expenses Employee benefits Depreciation and amortization Interest Contributions to Hospital		- 24 528 - - -	189,838 226,225 38,992 25,424 4,276	61,719 80,812 13,696 7,721 2,177	147,961 19,657 15,425 1,886	7,145 3,017 1,832 632 188	1,430 3,693 172 363 23	2,318 2,984 477 53 -	1,410 801 253 - -	- 9 - - - 3,059	7,242 - - - - -	(4,156) - - - -	411,821 340,308 71,375 36,079 6,664 3,059
Total expenses		552	484,755	166,125	184,929	12,814	5,681	5,832	2,464	3,068	7,242	(4,156)	869,306
(Loss) income from operations before other items		(549)	46,184	(752)	(48,502)	(4,303)	2,849	(1,696)	(120)	(9)	(3,086)	-	(9,984)
Other items Investment return Other		2,565	44,109 1,511	4,660 (618)	4 227	78	121	<u>-</u>		79 	4,748		56,364 1,120
Total other items		2,565	45,620	4,042	231	78	121			79	4,748		57,484
EXCESS OF (DEFICIENCY IN) REVENUE OVER EXPENSES	\$	2,016	\$ 91,804	\$ 3,290	\$ (48,271)	\$ (4,225)	\$ 2,970	\$ (1,696)	\$ (120)	\$ 70	\$ 1,662	\$ -	\$ 47,500